P.O. Box 970
Portage, MI 49081-0970
Phone: (269) 585-2100
Email: info@tolera.com

About Us

Tolera Therapeutics is a privately held company that is dedicated to improving the lives of patients suffering from a broad spectrum of autoimmune and immune-mediated diseases through targeted therapeutics.

We approach targeting the human alpha-beta T-cell receptor (αβTCR) that appears to render pathologic T-cells inert and through a unique signaling pathway that expands regulatory T-cells in a novel, non-depleting manner.

Tolera has brought together a team of experienced life science investors, executive leadership, translational medicine experts, clinical trialists, immunologists and scientific collaborators who believe these expanded regulatory T-cells are critical for long-term disease control. Our members are experienced in a wide breadth of disciplines which enable us to advance our company’s technology through clinical trials while also concentrating our internal efforts and resources on engineering and formulating second generation therapeutics focused on autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, systemic lupus, and inflammatory bowel disease.

Board of Directors

- Suzette Dutch, Chairman
- Harry Ledebur, Jr., PhD, CEO
- Douglas R. Morton, Jr., PhD
- Donald R. Parfet
- Mark Olesnavage